Page last updated: 2024-11-05

thalidomide and Reticulum Cell-Like Sarcoma, Yoshida

thalidomide has been researched along with Reticulum Cell-Like Sarcoma, Yoshida in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guidetti, E1
Moiraghi-Ruggenini, A1
Errigo, E1
Martelli, MP1

Other Studies

1 other study available for thalidomide and Reticulum Cell-Like Sarcoma, Yoshida

ArticleYear
[Immunodepressive action of thalidomide and prednisolone in rats with experimentally induced neoplasms].
    Il Cancro, 1969, Volume: 22, Issue:5

    Topics: Animals; Complement Fixation Tests; Immunosuppressive Agents; Prednisolone; Rats; Sarcoma, Yoshida;

1969